Added to YB: 2026-04-16
Pitch date: 2026-04-13
MEDP [bearish]
Medpace Holdings, Inc.
-3.45%
current return
Author Info
No bio for this author
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Market Cap
$14.3B
Pitch Price
$501.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
23.01
P/E
32.80
EV/Sales
5.51
Sector
Life Sciences Tools and Services
Category
value
SHORT: Medpace (NASDAQ: MEDP)
MEDP (short): CRO trades 23x EBITDA vs peers 11x on GLP-1 trial boom. Metabolic rev grew 45% CAGR since 2022 (~18% total rev), but Q4 cancellations spiked in obesity trials. Industry pricing collapsing (Novo/Lilly cutting 35-50%), semaglutide loses exclusivity 2026, VC funding down 20% YoY, trial retention worsening. Multiple should contract to pre-GLP era 18x as growth decelerates. >20% IRR, 2.0x R/R.
Read full article (19 min)